Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 63-67

  Antonaci, Alfredo ^a   Consorti, Fabrizio ^a   Mardente, Stefania ^a   Natalizi, Stefania ^a   Giovannone, Gloria ^a   Della Rocca, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti apoptotic protein; Proto oncogene; Thyroid neoplasm

Indexed keywords

CYCLIN D1; SURVIVIN; TUMOR MARKER; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CHILD; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID PAPILLARY CARCINOMA; THYROID PAPILLARY MICROCARCINOMA; CHEMISTRY; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PRESCHOOL CHILD; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; CHILD, PRESCHOOL; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; THYROID NEOPLASMS;

EID: 49849089049     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.63     Document Type: Article

References (18)

1. Sakorafas GH, Giotakis J and Stafyla V: Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev 31: 423-438, 2005.
2. Noguchi S, Yamashita H, Murakami N, et al: Small carcinomas of the thyroid. A long term follow up of 867 patients. Arch Surg 131: 187-191, 1996.
3. Chow SM, Law SC, Chan JK, et al: Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 98: 31-40, 2003.
4. Baudin E, Travagli JP, Ropers J, et al: Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83: 553-559, 1998.
5. Pearce EN and Braverman LE: Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab 89: 3710-3712, 2004. 6 Cheema Y, Olson S, Elson D and Chen H: What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res 134: 160-162, 2006.
6. Cappelli C, Castellano M, Braga M, et al: Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 95: 555-560, 2007.
7. Appetecchia M, Scarcello G, Pucci E and Procaccini A: Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res 21: 159-164, 2002.
8. Corapcioglu D, Sak SD, Delibasi T, et al: Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas. J Transl Med 4: 28-32, 2006.
9. Khoo ML, Ezzat S, Freeman JL and Asa SL: Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87: 1810-1813, 2002.
10. Hung HS, Wu WJ, Cheng YW, et al: Association of cooking oil fumes exposure with lung cancer: involvement of inhibitor of apoptosis proteins in cell survival and proliferation in vitro. Mutat Res 628: 107-116, 2007.
11. Ito Y, Yoshida H, Uruno T, et al: Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 10: 1337-1340, 2003.
12. Hay ID, Bergstralh EJ, Geollner JR, et al: Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1058, 1989.
13. Lantsov D, Meirmanov S, Nakashima M, et al: Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumor size and aberrant β-catenin expression. Histopathology 47: 248-256, 2005. 15 Duffy MJ, O'Donovan N, Brennan DJ, et al: Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60, 2007.
14. Haghpanah V, Shooshtarizadeh P, Heshmat R, et al: Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol 14: 422-425, 2006.
15. Li F, Yang J, Ramnath N, et al: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114: 509-512, 2005.
16. Stauber RH, Mann W and Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67: 5999-6002, 2007.
17. Loberg RD, Bradley DA, Tomlins S, et al: The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 57: 225-241, 2007.
18. Huang EH, Heidt DG, Li CW and Simeone DM: Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141: 415-419, 2007.